文献速递冠心病心力衰竭与心肌病

缺血性心肌病冠脉搭桥与药物治疗的成本效益:STICH随机临床试验

Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial.
PubMed 文献 · Circulation · 2022-01-19

基于STICH随机临床试验的患者水平数据,采用决策分析微观模拟模型评估冠脉搭桥(CABG)与单纯药物治疗(MED)在缺血性心肌病伴左心室功能减低(射血分数≤35%)患者中的终身成本与效益。

核心结论

  • 在STICH试验中,对缺血性心肌病伴左心室功能减低的患者,CABG相对于MED在美国当前价值基准下具有经济吸引力。

研究设计与样本

  • 采用决策分析患者水平模拟模型,基于STICH随机临床试验收集的患者水平资源使用和临床数据,估算CABG与MED的终身成本和效益。
  • 对未来成本和效益均应用3%贴现率,主要结局为从美国卫生保健部门视角评估的增量成本效益比。

临床怎么用

  • 对于缺血性心肌病伴射血分数≤35%的患者,CABG在美国支付意愿阈值下可视为具有经济吸引力的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure) demonstrated that coronary artery bypass grafting (CABG) reduced all-cause mortality rates out to 10 years compared with medical therapy alone (MED) in patients with ischemic cardiomyopathy and reduced left ventricular function (ejection fraction ≤35%). We examined the economic implications of these results. METHODS: We used a decision-analytic patient-level simulation model to estimate the lifetime costs and benefits of CABG and MED using patient-level resource use and clinical data collected in the STICH trial. Patient-level costs were calculated by applying externally derived US cost weights to resource use counts during trial follow-up. A 3% discount rate was applied to both future costs and benefits. The primary outcome was the incremental cost-effectiveness ratio assessed from the US health care sector perspective. RESULTS: For the CABG arm, we estimated 6.53 quality-adjusted life-years (95% CI, 5.70-7.53) and a lifetime cost of $140 059 (95% CI, $106 401 to $180 992). For the MED arm, the corresponding estimates were 5.52 (95% CI, 5.06-6.09) quality-adjusted life-years and $74 894 lifetime cost (95% CI, $58 372 to $93 541). The incremental cost-effectiveness ratio for CABG compared with MED was $63 989 per quality-adjusted life-year gained. At a societal willingness-to-pay threshold of $100 000 per quality-adjusted life-year gained, CABG was found to be economically favorable compared with MED in 87% of microsimulations. CONCLUSIONS: In the STICH trial, in patients with ischemic cardiomyopathy and reduced left ventricular function, CABG was economically attractive relative to MED at current benchmarks for value in the United States. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT00023595.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Chew DS, Cowper PA, Al-Khalidi H, et al. Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. Circulation. 2022. PMID: 35044802. doi:10.1161/CIRCULATIONAHA.121.056276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。